Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition.

A follow-on analysis of the phase 3 PSMAfore study conducted by the Dana-Farber Cancer Institute found that treatment with 177Lu-PSMA-617, a prostate-specific antigen (PSMA)-targeted radioligand therapy, was more effective than changing from one androgen receptor pathway inhibitor (ARPI) to another for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The trial enrolled 468 patients who had progressed after one prior ARPI treatment and had not received taxane chemotherapy. Treatment with 177Lu-PSMA-617 resulted in prolonged radiographic progression-free survival, improved PSA response rate, and increased objective response rate compared to changing ARPI. The results support considering 177Lu-PSMA-617 as a new standard treatment for this population of patients. The study was funded by Novartis. [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)